Mammoth Banks Ignore MOODY Critics as 3 Stocks Sizzle into Weekend

Morgan Stanley (NYSE:MS) spent the first quarter transferring $1 trillion (notional) in derivatives into its U.S. bank division, which currently has a rating one notch higher than the holding company, thus the derivatives located there will require lower collateral posting. At the same time, MS has approximately a $50 trillion exposure in notional derivatives.

Bank of America Corp (NYSE:BAC) and JPMorgan Chase (NYSE:JPM) were among the leading stocks in the Dow Jones industrial average on Friday, following Moody’s downgrades of the credit ratings on 15 large banks after market close on Thursday.

Don’t Miss: BIG Banks CLAWING Back for Redemption.

Facebook Inc (NASDAQ:FB) ads are beginning to move offsite to, to its dedicated platform that it introduced in March, which contains its own games as well as other popular games from other developers. There is no telling which other sites will begin to house Facebook ads and Sponsored Stories in the near future.

General Electric Company’s (NYSE:GE) GE Healthcare launches the GE Blueprint for low dose, which is a comprehensive program that helps healthcare providers combine CT technologies, education and process improvements, plus data analysis to shrink patient radiation doses from Computed Tomography (NYSE:CT), by as much as 50 percent. Moreover, GE Healthcare is committing to work with health systems and physicians in the development of system-specific solutions, which are comprehensive “blueprints” that can assist providers on achieving low-dose, high-definition diagnostic capabilities.

Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) shares reversed their recent gains, in the midst of heavy selling pressure. The origin of the stock’s troubles could be an article by Shane Blackmon at Seeking Alpha, which remarks that Arena’s rally has been driven by short-covering, as some 22 percent of the float was shorted as of May 31, and contends that “a bear raid seems inevitable,” prior to the FDA’s coming June 27 decision on the company’s Locaserin weight-loss drug.

Don’t Miss: SEC Pounces on Nasdaq Over Facebook IPO.

Want news like this in real-time so you can get an edge? Click here for Wall St. Cheat Sheet Pro.